Healthcare - Press Releases

SAN FRANCISCO and SUZHOU, China, Feb. 16, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology, and other major diseases, announced that its first-in-class PD-1/IL-2-bias bispecific antibody fusion protein, IBI363, has received its second Fast Track Designation (FTD) from the U.S. Food and Drug Administration (FDA). This designation applies to the treatment of unresectable, locally advanced, or metastatic squamous non-small cell lung cancer (sqNSCLC) that has progressed following anti-PD-(L)1 immune checkpoint inhibitor therapy and platinum-based chemotherapy. IBI363 has demonstrated encouraging efficacy and safety across multiple solid tumor types. Currently, Innovent is conducting Phase 1/2 clinical trials of IBI363 mainly in China and the U.S.

TAIPEI, Feb. 17, 2025 /PRNewswire/ -- Foresee Pharmaceuticals (TPEx: 6576), ("Foresee") today announces thethird positive safety review by the independentData and Safety Monitoring Board for its Casppian Phase 3 registration study. The DSMB recommended that Foresee Pharmaceuticalscontinue the trial as planned without any modification.

Jauna slimncas gulta paldz aprptjiem nodroint efektvu un kvalitatvu aprpi tirgos rpus ASV.

Uus haiglavoodi aitab hooldajatel pakkuda thusat ja kvaliteetset hooldust turgudel vljaspool USA-d

Nauja ligonins lova padeda slaugytojams teikti veiksming ir kokybik prieir rinkose u JAV rib.

OSLO, Norway, Feb. 17, 2025 /PRNewswire/ -- Photocure ASA (OSE: PHO),The Bladder Cancer Company, announces the presentation on February 14 of a new abstract with study results from its U.S. bladder cancer patient registry at the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO-GU), in San Francisco. The abstract discusses the role of Blue Light Cystoscopy in identifying tumors undetected by WLC leading to necessary upstaging of patient pathology. Consequently, when using Blue Light Cystoscopy with Cysview, bladder cancer management decisions can be made more appropriately.

OSLO, Norway, Feb. 17, 2025 /PRNewswire/ -- Photocure ASA (OSE: PHO),The Bladder Cancer Company, announces the presentation on February 14 of a new abstract with study results from its U.S. bladder cancer patient registry at the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO-GU), in San Francisco. The abstract discusses the role of Blue Light Cystoscopy in identifying tumors undetected by WLC leading to necessary upstaging of patient pathology. Consequently, when using Blue Light Cystoscopy with Cysview, bladder cancer management decisions can be made more appropriately.

RIGA, Latvia, Feb. 17, 2025 /PRNewswire/ -- The leading pharmaceutical company in theBaltics,Grindeks, continues to strengthen its global presence by entering new export markets. This year, for the first time,Grindeks products will be delivered to Panama. The company's export markets already include countries such as Chile, Mexico, Australia, Singapore, the Philippines, and most of Europe. Active pharmaceutical ingredients are also exported to Japan, South Korea, and the USA.

RIGA, Latvia, Feb. 17, 2025 /PRNewswire/ -- The leading pharmaceutical company in theBaltics,Grindeks, continues to strengthen its global presence by entering new export markets. This year, for the first time,Grindeksproducts will be delivered to Panama. The company's export markets already include countries such as Chile, Mexico, Australia, Singapore, the Philippines, and most of Europe. Active pharmaceutical ingredients are also exported to Japan, South Korea, and the USA.

Neues Krankenhausbett hilft Pflegekrften bei der effizienten und qualitativ hochwertigen Versorgung in Mrkten auerhalb der USA.

New hospital bed helps caregivers deliver efficient and quality care in markets outside the U.S.

- Una nueva cama hospitalaria ayuda a los cuidadores a prestar una asistencia eficaz y de calidad en mercados fuera de Estados Unidos

Die bahnbrechende, randomisierte MASAI-Studie zeigt, dass die Anwendung von Transpara zu einer signifikanten Steigerung der Frherkennungsrate im Mammographiescreening sowie zu einer deutlich krzeren Befundungszeit fhrt.

Global Financial Market Review (GFM) is a dedicated online news aggregation portal specializing in financial market news and industry updates. It combines original editorials with curated content from global news providers, reaching over 14 million readers annually. With a focus on reliability and depth, GFM has positioned itself as a trusted source in the financial sector, boasting a strong social media presence with over 180,000 Twitter followers.

IZERVAY dosing approved beyond 12 months

InterCure Logo (PRNewsfoto/InterCure Ltd.)

Highlights:

CHANDLER, Ariz., Feb. 12, 2025 /PRNewswire/ --Embark Behavioral Health, a leader in youth and young adult mental health care, is reaffirming its commitment to creating joy and healing generations. Under the leadership of Scott Filion, CEO, and Dr. Sharnell Myles, Psy.D., Chief Clinical Officer, the company is fortifying its mission through a revitalized clinical leadership team and expanding their current services to offer integrated mental health.

OMAHA, Neb., Feb. 12, 2025 /PRNewswire/ -- IHS, LLC., a leading business acquisitions and management firm, along with its physician partners, proudly announces the successful acquisition of BC Healthcare, a distinguished specialty medical practice recognized for its advanced healthcare services. This strategic acquisition marks a significant milestone in IHS, LLC.'s commitment to expanding high-quality, patient-centered care and elevating healthcare standards in Omaha, Nebraska, and beyond.

PRINCETON, N.J., Feb. 12, 2025 /PRNewswire/ --Palindrome Technologies has been recognized as an official testing facility for the IEEE Medical Device Cybersecurity Certification Program, positioning the company at the forefront of medical device security. This certification program, launched in 2023 by the IEEE 2621 Conformity Assessment Committee (CAC), offers a comprehensive evaluation process tailored specifically for medical devices in an increasingly connected healthcare landscape.

HONG KONG, Feb. 12, 2025 /PRNewswire/ --Akeso, Inc. (9926. HK) ("Akeso" or the "Company") announced the recent completion of the first patient enrollment in the Phase 3 randomized, double-blind, multicenter clinical trial (COMPASSION-30/AK104-309) for its independently developed PD-1/CTLA-4 bispecific antibody, cadonilimab. This study is evaluating the efficacy of cadonilimab compared to sugemalimab (PD-L1) as a consolidation therapy for patients with locally advanced, non-resectable, non-small cell lung cancer (NSCLC) who have not experienced disease progression following concurrent or sequential chemoradiotherapy.

NEW YORK, LONDON, MNCHEN und NEU-DELHI, 13. Februar 2025 /PRNewswire/ -- Datar Cancer Genetics (DCG), gibt die Ernennung von Dr. Massimo Cristofanilli, MD, zum strategischen Berater bekannt. DCG ist ein weltweit fhrendes Unternehmen im Bereich der nicht-invasiven Krebsdiagnostik. Mit diesem Schritt unterstreicht DCG sein Engagement fr die Weiterentwicklung der Krebsfrherkennung und Przisionsmedizin.

CHENGDU, China, Feb. 12, 2025 /PRNewswire/ -- At the American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium 2025, to be held in San Francisco, USA, from Feb. 13-15, 2025,Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd "Kelun-Biotech" will present efficacy and safety results from the Phase 1/2 KL264-01/MK-2870-001 study (NCT04152499) of its anti-TROP2ADC sacituzumab tirumotecan (sac-TMT, formerly SKB-264/MK-2870) as monotherapy in patients with unresectable, locally advanced or metastatic urothelial carcinoma (UC) who progressed on or after prior anti-cancer therapies. These findings will be presented in a poster session on February 14, 2025, local time (Abstract #796).

SEOUL, South Korea, Feb. 13, 2025 /PRNewswire/ -- DAAN Biotherapeutics, a leading innovative drug development company specializing in T-cell receptor (TCR)- based therapies, has signed an exclusive licensing agreement with LigaChem Biosciences for a novel tumor-targeting antibody to advance the development and commercialization of Antibody-Drug Conjugates (ADC).

TOKYO, Feb. 13, 2025 /PRNewswire/ --Restore Vision Inc., a clinical-stage biotechnology company advancing gene therapies for retinal disorders, today announced that the first patient in its Phase I/II clinical trial with RV-001 has been dosed atKeio University Hospital. RV-001 utilizes adeno-associated virus (AAV) vectors to deliver a unique functional gene encoding "Chimeric Rhodopsin", a light-driven G-protein activation mechanism to re-establish light activation in retinal interneurons. The goal is to expand light sensitivity to retinal interneurons via an intravitreal injection of RV-001. This milestone marks the initiation of the world's first clinical trial of optogenetic gene therapy, which leverages a proprietary "Chimeric Rhodopsin" for patients with retinitis pigmentosa (RP). "Over 2 million people worldwide suffer photoreceptor loss in retinitis pigmentosa, resulting in severe vision loss and eventual blindness" said, CEO and Ophthalmologist Yusaku Katada, MD, PhD. "Our "chimeric rhodopsin" approach has broad potential to alter light sensitivity across multiple subtypes of RP patients.[1] We are continuing to advance the Phase I/II trial to assess safety, light-activation and light-sensitivity in these patients, post-administration of our lead gene therapy product RV-001."